Editas Medicine said Thursday afternoon it will lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell disease and shifts focus.

In October, Editas revealed plans to change course, announcing that it would seek to license out its lead CRISPR medicine for sickle cell disease. That search did not identify a commercial partner, ...

Researchers expand the CRISPR genome engineering toolbox with transposase-assisted target-site integration (TATSI), a ...

In-vivo gene editing, which alters genetic material within the patient, could expand the potential of CRISPR-based gene editing, Editas said. The company said it aims to demonstrate proof of concept ...

How does CRISPR work, and why is editing human embryos so controversial? Explore the science, the risks, and the ethical debates surrounding Dr. He Jiankui’s gene-editing experiment.

Research analysts at William Blair issued their FY2024 earnings per share estimates for shares of CRISPR Therapeutics in a report issued on Monday, December 9th. William Blair analyst S. Corwin ...

The Cambridge, Mass.-based company on Thursday said it will now focus on in vivo Crispr-edited medicines based on its researchers recent scientific progress in multiple tissues. At the same time, it ...

Dozens of top scientists are warning that creating synthetic "mirror bacteria," composed of biomolecules that are the mirror ...

When hiring job candidates to work on cell and gene therapies, companies look for more than just technical skills. Talent ...

DelveInsight's Hematology Market Insights report provides the current and forecast market analysis, individual leading ...

I am glad that these negative results are finally shared, as it helps prevent duplication of work and unnecessary suffering in laboratory animals.” ...

The era of artificial intelligence has already begun and we talk more about its risks than its possibilities. Can we allow ...